Trial
NCT05001724
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Collaborators
—
Condition
Advanced Non-small Cell Lung Cancer
Intervention
KN046
Why stopped
Because the efficacy data did not meet expectations, the sponsor decided to terminate the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-25